Teneligliptin Versus Linagliptin in Diabetes Mellitus Type Two Patients
Launched by HANDOK INC. · Jan 4, 2017
Trial Information
Current as of June 29, 2025
Completed
Keywords
ClinConnect Summary
A randomized, open label, parallel-group, non-inferiority, active-controlled, phase IV study
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients who are 19 years or older on screening
- • Patients with type 2 diabetes mellitus
- • Patients with 7.0% ≤ HbA1c ≤ 11.0% at the screening visit
- • Patients with Fasting Plasma Glucose \<15mmol/L(270mg/dL) on screening
- Exclusion Criteria:
- • -
About Handok Inc.
Handok Inc. is a leading biopharmaceutical company based in South Korea, dedicated to advancing innovative therapies for a range of medical conditions. With a strong focus on research and development, Handok collaborates with global partners to enhance drug discovery and improve patient outcomes. The company specializes in various therapeutic areas, including oncology, immunology, and rare diseases, and is committed to adhering to the highest standards of clinical research and regulatory compliance. Handok’s mission is to deliver transformative healthcare solutions that meet the evolving needs of patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Seoul, , Korea, Republic Of
Seoul, , Korea, Republic Of
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials